Medical management of Cushing's disease: what is the future?
about
The Treatment of Cushing's Disease.Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapiesUpdate on medical treatment for Cushing's disease.Global clinical response in Cushing's syndrome patients treated with mifepristoneChanges in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.Past and present in abdominal surgery management for Cushing's syndromeOsilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Pharmacoeconomic aspects of the treatment of pituitary gland tumours.New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapyMonitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease.Lateral transorbital neuroendoscopic approach to the lateral cavernous sinus.Characterization of persistent and recurrent Cushing's diseaseRecent advances in the medical treatment of Cushing's disease.Mifepristone: is there a place in the treatment of Cushing's disease?Pasireotide: a review of its use in Cushing's disease.Aggressive pituitary adenomas--diagnosis and emerging treatments.Cushing's syndrome: from physiological principles to diagnosis and clinical care.Current status on histological classification in Cushing's disease.Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.Bilateral adrenalectomy for Cushing's disease.New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.Pituitary-directed medical therapy in Cushing's disease.Medical combination therapies in Cushing's disease.Emerging drugs for Cushing's disease.Is there a role for early chemotherapy in the management of pituitary adenomas?Ketoconazole Treatment Decreases the Viability of Immortalized Pituitary Cell Lines Associated with an Increased Expression of Apoptosis-Related Genes and Cell Cycle Inhibitors.Currently used and investigational drugs for Cushing´s disease.Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience.Glucose intolerance induced by glucocorticoid excess is further impaired by co-administration with β-hydroxy-β-methylbutyrate in rats.Dimethoxy-etomidate: A Non-hypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.Pituitary-Directed Therapies for Cushing's Disease.New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.Inhibitory Effects of a Novel PPAR-γ Agonist MEKT1 on Pomc Expression/ACTH Secretion in AtT20 Cells.
P2860
Q27010590-146EE309-39A1-4512-98B1-A3BE87183026Q28076013-48EBE700-73CB-4310-BEF7-E319CDBEBFD4Q33802284-4A4D6650-201B-42EE-B27D-AB18F5F1F6C8Q34629187-133AFD52-06BC-4CDD-9E65-8D55E136AB3AQ35441693-E67AF0A8-315E-469F-B99B-BBB59CD9F7BCQ36165895-4692DE6B-D7EB-4E7B-9A5C-10CCE0631F03Q36704499-6D9B5659-E048-498B-82F4-741072B4168CQ36936833-1A5F537E-5658-46DB-A6E9-DB7BBEEBF750Q37049132-02CCE4D9-9524-463F-9C8F-40BA17FD6988Q37322951-03E27B26-D02F-40BE-8FEA-F69CA68D106DQ37549161-32C38ADA-607F-4791-AB90-19DF15FFB909Q37610803-80702B65-EF7E-42D2-B858-84E89BD3DF1CQ37621524-3924C79B-B2A6-45DE-9B9C-59B380B1C7ABQ38063404-3B682AE7-D7DF-417D-B4FE-53DD7B1B172EQ38100715-3A0E6B24-F8C9-4ADE-AFC5-80C9D784561AQ38211375-CE010F0E-6CDD-47F4-B610-EFE8E092A496Q38284048-98C50690-B2C4-4ED8-8970-775047F52F73Q38287030-C8D28F0C-FD03-412E-8590-E74D3CD2AFABQ38307934-6F1A6FC7-42FE-426E-AC93-ADD7CA9DF31BQ38310473-C85E934A-F31A-4839-84A5-F6800B49EBDDQ38328843-0FEA3B75-EEFB-4662-B3A3-450FF64ED076Q38334659-A4739A9F-641C-4FC7-862C-BD876E0065A0Q38342520-B97392EB-BA89-4257-98F8-1F7143DF85A0Q38505947-4E5C4958-2DA1-4F12-A5D6-B9CFDD36D467Q38815400-4B253166-5854-41F8-B088-16E6EEA4F65CQ38895207-D7140359-96B1-47F7-A9AD-0496F9F4A832Q39022297-75A81836-C5F6-40C3-9561-DE2C9B20B235Q44498517-39AEA024-CA3F-42B8-9171-A3A5C02C98EEQ46476511-CD8FC0A6-1F21-46B9-BA3B-8BB544BA2569Q47224599-991CD63C-C00A-4174-8930-4D506732905CQ54961209-C7E3CE0C-0138-4B1B-886F-8A6AFDD8BF35Q55249109-2E506C47-EB24-4CB2-9C7A-ECB0D56E32AFQ55423757-228BB80A-189B-4520-B834-A7892E06D198
P2860
Medical management of Cushing's disease: what is the future?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Medical management of Cushing's disease: what is the future?
@ast
Medical management of Cushing's disease: what is the future?
@en
type
label
Medical management of Cushing's disease: what is the future?
@ast
Medical management of Cushing's disease: what is the future?
@en
prefLabel
Medical management of Cushing's disease: what is the future?
@ast
Medical management of Cushing's disease: what is the future?
@en
P2860
P921
P1433
P1476
Medical management of Cushing's disease: what is the future?
@en
P2093
Stephan Petersenn
P2860
P2888
P304
P356
10.1007/S11102-012-0397-5
P577
2012-09-01T00:00:00Z